Gemcitabine vs Gemcitabine (FF-10832)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ribonucleotide reductase / DNA polymerase (dCTP competition) · full Non-Small Cell Lung Cancer pipeline

Gemcitabine

Rights held by Eli Lilly; US product discontinued

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT00003589 · Phase 3 · completed

This Phase 3 trial randomly assigned 450 people with advanced lung cancer to one of three chemotherapy combinations: paclitaxel with cisplatin, gemcitabine with cisplatin, or paclitaxel with gemcitabine. The registry does not say whether or how treatment assignment was masked. Median overall survival was 8.9 months on gemcitabine with cisplatin, 8.1 months on paclitaxel with cisplatin and 6.7 months on paclitaxel with gemcitabine, with response rates of 36.6%, 31.8% and 27.7%. The published report gives these figures without a statistical comparison between the arms, so no combination can be called the winner on this evidence.

Next expected readout: December 2026 · NCT02889666 (registry estimate)

Reported efficacy

Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively (unclear)

Result source: NCT00003589

Gemcitabine (FF-10832)

Developed by Fujifilm Pharmaceuticals U.S.A., Inc.

Phase 2 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2029 · NCT05318573 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGemcitabineGemcitabine (FF-10832)
PFS, median5.1 vs 5.5vs Chemotherapyn 396NCT02477826
21 other results
—Not reported
OS, median85.8n 752NCT00324805
26 other results
—Not reported
ORR36.4% vs 29.7%vs Chemotherapyn 396NCT02477826
17 other results
—Not reported
Duration of response, median5.5 vs 4.5vs Pem + Carb or Cisn 34NCT01160744
7 other results
—Not reported

PFS, median

Gemcitabine
5.1 vs 5.5vs Chemotherapyn 396NCT02477826
21 other results
Gemcitabine (FF-10832)
—Not reported

OS, median

Gemcitabine
85.8n 752NCT00324805
26 other results
Gemcitabine (FF-10832)
—Not reported

ORR

Gemcitabine
36.4% vs 29.7%vs Chemotherapyn 396NCT02477826
17 other results
Gemcitabine (FF-10832)
—Not reported

Duration of response, median

Gemcitabine
5.5 vs 4.5vs Pem + Carb or Cisn 34NCT01160744
7 other results
Gemcitabine (FF-10832)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Gemcitabine (FF-10832): no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Gemcitabine: 4 of 4 rows · Gemcitabine (FF-10832): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGemcitabine
Dropout rate
64.2%a
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
show 32 more results
0.9%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · registry result, not featured evidence · combination
1.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3 · registry result, not featured evidence
1.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
1.1%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
2.8%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
0.5%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
12.7%
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
9.4%
NCT00478699 · Phase 3 · registry result, not featured evidence
9.8%
NCT00499109 · Phase 3 · registry result, not featured evidence
5.6%Ram + Gem + Carb or Cis (Squamous)
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
7.2%Ram + Pem + Carb or Cis (Non-Squam
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT01951157 · Phase 2 · registry result, not featured evidence · combination
7.7%
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
13.1%
NCT01788566 · Phase 2 · registry result, not featured evidence · combination
81.8%Bevacizumab + Gemcitabine
NCT01077713 · Phase 2 · registry result, not featured evidence · combination
85.7%Bevacizumab + Gemcitabine + Cispla
NCT01077713 · Phase 2 · registry result, not featured evidence · combination
0%2000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
33.3%2000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
100%1000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
66.7%1000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
—Once Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
—Twice Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
1.7%Paclitaxel, Carboplatin, Cetuximab
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
1.7%Platinum, Gemcitabine, Cetuximab (
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
3.1%Platinum, Pemetrexed, Cetuximab (A
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
16.7%GCC Plus Cixutumumab
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
20%GCiC Plus Cixutumumab
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
—ZD6474 (Gemcitabine), Vandetanib
NCT00753714 · Phase 2 · registry result, not featured evidence · combination
98.4%ZD6474 (Vandetanib),Gemcitabine
NCT00753714 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT00735904 · Phase 2 · registry result, not featured evidence · combination
78.9%
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
27%a
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
show 32 more results
0%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · registry result, not featured evidence · combination
0.3%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3 · registry result, not featured evidence
0%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
0.5%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
0%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
0.3%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
0%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
—
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
—
NCT00478699 · Phase 3 · registry result, not featured evidence
—
NCT00499109 · Phase 3 · registry result, not featured evidence
—Ram + Gem + Carb or Cis (Squamous)
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
—Ram + Pem + Carb or Cis (Non-Squam
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
—
NCT01951157 · Phase 2 · registry result, not featured evidence · combination
—
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT01788566 · Phase 2 · registry result, not featured evidence · combination
4.5%Bevacizumab + Gemcitabine
NCT01077713 · Phase 2 · registry result, not featured evidence · combination
2.4%Bevacizumab + Gemcitabine + Cispla
NCT01077713 · Phase 2 · registry result, not featured evidence · combination
0%2000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
0%2000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
0%1000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
33.3%1000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
—Once Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
—Twice Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
—Paclitaxel, Carboplatin, Cetuximab
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
—Platinum, Gemcitabine, Cetuximab (
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
—Platinum, Pemetrexed, Cetuximab (A
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
0%GCC Plus Cixutumumab
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
8%GCiC Plus Cixutumumab
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
—ZD6474 (Gemcitabine), Vandetanib
NCT00753714 · Phase 2 · registry result, not featured evidence · combination
42.6%ZD6474 (Vandetanib),Gemcitabine
NCT00753714 · Phase 2 · registry result, not featured evidence · combination
7.9%
NCT00735904 · Phase 2 · registry result, not featured evidence · combination
—
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
76.6%a
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
show 32 more results
27%3 mg/kg + 1 mg/kg
NCT02998528 · Phase 3 · registry result, not featured evidence · combination
61.1%Part 1-Arm A: Nivolumab
NCT02477826 · Phase 3 · registry result, not featured evidence
70.3%Part 1-Arm B: Nivo + Ipi
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
69.2%Part 1-Arm D: Nivo + Ipi
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
65.1%Part 1-Arm G: Nivo + Chemo
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
64%Part 2 - Arm H: Nivolumab + Chemot
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
61.9%Part 3 -Arm J: Nivolumab + Ipilimu
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
48.7%
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
—
NCT00478699 · Phase 3 · registry result, not featured evidence
—
NCT00499109 · Phase 3 · registry result, not featured evidence
54.9%Ram + Gem + Carb or Cis (Squamous)
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
65.7%Ram + Pem + Carb or Cis (Non-Squam
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
72%
NCT01951157 · Phase 2 · registry result, not featured evidence · combination
69.4%
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
54.1%
NCT01788566 · Phase 2 · registry result, not featured evidence · combination
39.5%Bevacizumab + Gemcitabine
NCT01077713 · Phase 2 · registry result, not featured evidence · combination
25%Bevacizumab + Gemcitabine + Cispla
NCT01077713 · Phase 2 · registry result, not featured evidence · combination
33.3%2000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
0%2000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
0%1000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
66.7%1000 mg
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
49.4%Once Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
58%Twice Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
46.4%Paclitaxel, Carboplatin, Cetuximab
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
54.2%Platinum, Gemcitabine, Cetuximab (
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
52.3%Platinum, Pemetrexed, Cetuximab (A
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
83.3%GCC Plus Cixutumumab
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
60%GCiC Plus Cixutumumab
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
42.6%ZD6474 (Gemcitabine), Vandetanib
NCT00753714 · Phase 2 · registry result, not featured evidence · combination
—ZD6474 (Vandetanib),Gemcitabine
NCT00753714 · Phase 2 · registry result, not featured evidence · combination
39.5%
NCT00735904 · Phase 2 · registry result, not featured evidence · combination
10.5%
NCT00701558 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
creatinine increased 33.6%
neutrophil count decreased 32.1%
anemia 24.9%
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
show 29 more results
3 mg/kg + 1 mg/kg
constipation 21.6%
fatigue 21.6%
nausea 21.6%
NCT02998528 · Phase 3 · registry result, not featured evidence · combination
decreased appetite 24.8%
dyspnoea 23.8%
diarrhoea 22.5%
NCT02477826 · Phase 3 · registry result, not featured evidence
decreased appetite 33.2%
fatigue 27.4%
diarrhoea 26.1%
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
decreased appetite 33%
dyspnoea 25.4%
diarrhoea 23.8%
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
anaemia 46.5%
nausea 45.9%
constipation 36.6%
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
anaemia 46.4%
nausea 33.6%
decreased appetite 28%
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
anaemia 50%
hyponatraemia 37.3%
aspartate aminotransferase increased 36.5%
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
nausea 49.3%
rash 46.8%
anaemia 41.1%
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
neutropenia 73.2%
fatigue 54.9%
anaemia 53.5%
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
fatigue 65.7%
nausea 52.2%
anaemia 47.8%
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
asthenia/fatigue 68%
anaemia 60%
nausea 52%
NCT01951157 · Phase 2 · registry result, not featured evidence · combination
fatigue: induction 88.9%
hypertension grade: end of induction 88.9%
anemia: induction 75%
NCT00655850 · Phase 2 · registry result, not featured evidence · combination
nausea 73.8%
decreased appetite 57.4%
rash 45.9%
NCT01788566 · Phase 2 · registry result, not featured evidence · combination
neutropenia 27.9%
hypertension 25.6%
asthenia 20.9%
NCT01077713 · Phase 2 · registry result, not featured evidence · combination
neutropenia 57.5%
nausea 42.5%
thrombocytopenia 40%
NCT01077713 · Phase 2 · registry result, not featured evidence · combination
2000 mg
rash 100%
alopecia 66.7%
diarrhoea 66.7%
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
2000 mg
rash 100%
leukopenia 66.7%
anorexia 33.3%
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
1000 mg
epistaxis 100%
fatigue 100%
rash 100%
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
1000 mg
anorexia 100%
fatigue 100%
haemoglobin decreased 100%
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
Once Weekly
nausea 57.6%
neutropenia 49.4%
rash 41.2%
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
Twice Weekly
nausea 52%
anaemia 42%
neutropenia 42%
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
fatigue 55.7%
weight decreased 50.6%
nausea 41.7%
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
fatigue 55.5%
thrombocytopenia 51.7%
anemia 44.5%
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
fatigue 58.5%
nausea 46.9%
weight decreased 43.1%
NCT00828841 · Phase 2 · registry result, not featured evidence · combination
dermatitis acneiform 83.3%
fatigue 66.7%
neutropenia 66.7%
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
thrombocytopenia 76%
constipation 68%
fatigue 68%
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
pyrexia 27.9%
rash 24.6%
fatigue 23%
NCT00753714 · Phase 2 · registry result, not featured evidence · combination
nausea 42.1%
anaemia 28.9%
vomiting 28.9%
NCT00735904 · Phase 2 · registry result, not featured evidence · combination
anaemia of malignant disease 36.8%
thrombocytopenia 31.6%
rash 15.8%
NCT00701558 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Gemcitabine

Overall Survival 85.8 vs NA Chemotherapy months
time to event · months
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
show 14 more results
17.12 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
15.7 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence
17.45 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
15.21 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
18.27 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
20.99 vs 14.88 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
11.5 vs 9.9 Gemcitabine + Cisplatin months
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
13.9 vs 10.4 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
10.4 vs 10.4 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
7.2 vs 9.4 Docetaxel months
NCT01951157 · Phase 2 · registry result, not featured evidence · combination
13.6 vs 9.7 Cetuximab + Chemotherapy monthsOnce Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
13.6 vs 9.7 Cetuximab + Chemotherapy monthsTwice Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
8.9 vs 11.5 GCiC months
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
8.61 vs 10.02 Gemcitabine months*
NCT00753714 · Phase 2 · registry result, not featured evidence · combination · converted to months from 262 days as posted
Disease-free Survival 40.6 vs 42.9 Chemotherapy months
time to event · months
NCT00324805 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
32.7 vs 38.7 Control Arm months
NCT00478699 · Phase 3 · registry result, not featured evidence
PFS 5.06 vs 5.55 Chemotherapy months
time to event · months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
show 16 more results
4.17 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence
4.9 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
5.55 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
8.34 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
5.78 vs 5.55 Chemotherapy months
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
5.7 vs 5.5 Gemcitabine + Cisplatin months
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
9.7 vs 4.2 Gemcitabine +Carboplatin months
NCT01404260 · Phase 3 · registry result, not featured evidence · combination
7.2 vs 5.6 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
5.6 vs 5.6 Pem + Carb or Cis months
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
3.3 vs 3.1 Docetaxel months
NCT01951157 · Phase 2 · registry result, not featured evidence · combination
6.2 vs 5 Cetuximab + Chemotherapy monthsOnce Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
5.6 vs 5 Cetuximab + Chemotherapy monthsTwice Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
5.6 vs 5.3 Cetuximab + Chemotherapy monthsOnce Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
5.6 vs 5.3 Cetuximab + Chemotherapy monthsTwice Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
5.6 vs 4.2 GCiC months
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
6.01 vs 5.55 Gemcitabine months*
NCT00753714 · Phase 2 · registry result, not featured evidence · combination · converted to months from 183 days as posted
ORR 36.4% (n=396) vs 29.7% (n=397) Chemotherapy
responder rate · % of participants
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
show 12 more results
27.5% (n=396) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · registry result, not featured evidence
26.2% (n=187) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
37.9% (n=177) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
52.3% (n=377) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
38.1% (n=126) vs 29.7% (n=397) Chemotherapy
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
31.2% (n=545) vs 28.8% (n=548) Gemcitabine + Cisplatin
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
49.3% (n=69) vs 38% (n=71) Pem + Carb or Cis
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
46.5% (n=71) vs 38% (n=71) Pem + Carb or Cis
NCT01160744 · Phase 2 · registry result, not featured evidence · combination
17.4% (n=23) vs 9.1% (n=22) Docetaxel
NCT01951157 · Phase 2 · registry result, not featured evidence · combination
37.6% (n=85) vs 29.8% (n=84) Cetuximab + ChemotherapyOnce Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
27.5% (n=51) vs 29.8% (n=84) Cetuximab + ChemotherapyTwice Weekly
NCT00842712 · Phase 2 · registry result, not featured evidence · combination
20% (n=25) vs 31% (n=29) Gemcitabine/Cisplatin/Cetuximab (GCiC)
NCT00870870 · Phase 2 · registry result, not featured evidence · combination
LCSS Symptom Deterioration 31.3% (n=396) vs 25.7% (n=397) Chemotherapy @ 12wk
ratio to baseline · % of baseline
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
show 5 more results
35.4% (n=396) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · registry result, not featured evidence
33.2% (n=187) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
28.8% (n=177) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
30% (n=377) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
23% (n=126) vs 25.7% (n=397) Chemotherapy @ 12wk
NCT02477826 · Phase 3 · registry result, not featured evidence · combination
Time to Treatment Failure 4.3 vs 3.6 Gemcitabine + Cisplatin months
time to event · months
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
EQ-5D -0.0053 vs -0.0083 Gemcitabine + Cisplatin score @ 18wk
absolute change · score
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
Fatigue VAS 6.3 vs 3.5 Gemcitabine + Cisplatin mm @ 18wk
absolute change · mm
Fatigue (n=302, 242)
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
Cough VAS -7.8 vs -9.1 Gemcitabine + Cisplatin mm @ 18wk
absolute change · mm
Cough (n=303, 243)
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
Pain VAS -3.3 vs -2.2 Gemcitabine + Cisplatin mm @ 18wk
absolute change · mm
Pain (n=302, 243)
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
LCSS -0.8 vs -0.8 Gemcitabine + Cisplatin mm @ 18wk
absolute change · mm
LCSS Total Score (n=290, 228)
NCT00981058 · Phase 3 · registry result, not featured evidence · combination
PFS 6mo 52% (n=183) vs 56.5% (n=92) C. Standard of Care Control Arm @ 26wk
absolute value · percentage points
NCT00499109 · Phase 3 · registry result, not featured evidence

+ 27 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gemcitabine's landscape · Gemcitabine (FF-10832)'s landscape